- Home
- CAPR
as 11-08-2024 12:32pm EST
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
Upcoming Earnings Alert:
Get ready for potential market movements as Capricor Therapeutics Inc. CAPR prepares to release earnings report on 13 Nov 2024.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | BEVERLY HILLS |
| Market Cap: | 332.5M | IPO Year: | N/A |
| Target Price: | $35.50 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.68 - $23.40 | Next Earning Date: | 11-13-2024 |
| Revenue: | $27,152,218 | Revenue Growth: | 187.15% |
| Revenue Growth (this year): | -34.57% | Revenue Growth (next year): | 135.53% |
Stock Insider Trading Activity of Capricor Therapeutics Inc. (CAPR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Nippon Shinyaku Co Ltd | CAPR | 10% Owner | Sep 20 '24 | Buy | $5.36 | 2,798,507 | $14,999,997.52 | 7,090,351 |
Latest Capricor Therapeutics Inc. News
CAPR Breaking Stock News: Dive into CAPR Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Is Capricor Therapeutics (CAPR) Outperforming Other Medical Stocks This Year?
Zacks
a day ago
Prestige Consumer Healthcare (PBH) Meets Q2 Earnings Estimates
Zacks
2 days ago
Verano Holdings Corp. (VRNOF) Expected to Beat Earnings Estimates: Should You Buy?
Zacks
3 days ago
Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to Decline
GlobeNewswire
3 days ago
Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13
Simply Wall St.
14 days ago
High Growth Tech Stocks to Watch in October 2024
MT Newswires
18 days ago
Piper Sandler Initiates Capricor Therapeutics at Overweight With $35 Price Target
MT Newswires
21 days ago
Capricor Therapeutics Closes Underwritten Public Offering
Compare CAPR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CAPR Capricor Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.